Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
CLC3E sub-study titled: An Economic Analysis of Early VS Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Companion Analysis to CCTG CLC.3 / SWOG 1925 Randomized
Dr. Jonathan Loree has been recognized for his Phase III research contributions with the CCTG 2022 Dr. Ralph Meyer Phase III Young Investigator Award.
CCTG congratulates BC Cancer Vancouver GCC1 Trial Team whose work was recognized with the 2022 CCTG Phase III Team Award, for performance in trial accrual, local activation timelines, compliance metrics and team performance.
The Dr. Joseph Pater Founder’s Award has been presented to Dr. Warren Mason, MD, FRCPC for his excellence in clinical trials research, leadership and his body of work that has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
CCTG congratulates the Hotel-Dieu du Quebec MA39 trial team for their CCTG Phase III Team Award presented at the CCTG 2022 Spring Meeting.
The award is given to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance. The team includes, Alexandre Villeneuve-Gauthier, Josee Allard, Dr. Valerie Theberge, Sophie Pouliot, Isabelle Desrosiers.
Dr. Aly-Khan A. Lalani, B.Sc (Hons), MD, FRCPC, has been awarded the 2022 CCTG Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award recognizing his work as a new investigator who has contributed significantly to the conduct of an IND trials.
The Allan Blair Cancer Centre IND234 trial team has been awarded the 2022 CCTG IND Team Award for performance in trial accrual, local activation timelines, and compliance metrics, team performance.
